MIV files three new U.S. patents for stroke-preventing technology

By Elaine Rigoli

Tampa, Fla., Aug. 18 - MIV Therapeutics said its subsidiary, SagaX, has filed three new patents with the U.S. Patent and Trademark Office related to a proprietary implantable filtration device designed to help prevent common stoke complications during and after a range of common invasive heart procedures.

The market for this device is estimated to exceed $1.5 billion to $1.8 billion by 2009, the company said in a news release.

The three recent SagaX patent applications cover different types of filtration device configurations and the use of different filtration technologies. These include designs and systems to position the device within the aorta below the carotid arteries and systems to retrieve the embolic protection devices via a catheter after several weeks or months.

These systems will enable physicians to use the devices for many types of procedures, giving them the flexibility to either remove the device or leave it in situ (implanted), the release said.

Atlanta-based MIV is a biotechnology company focusing on coatings for cardiovascular stents.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.